ID
45556
Descripción
Principal Investigator: Barry S. Taylor, PhD, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA MeSH: Ureteral Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000706 Outlier analyses represent a versatile method to identify predictive biomarkers of response to both targeted agents and chemotherapy. We performed whole genome sequencing (WGS) of tumor and germline blood from a patient with metastatic small cell carcinoma of the ureter who experienced a durable complete response to a combination of irinotecan plus AZD7762, a checkpoint kinase inhibitor. The patient initially had resection of the ureter followed by metastatic recurrence within the kidney and lymph nodes and underwent nephrectomy with lymph node dissection. Through WGS of tissue from the second surgery, we detected a hypomorphic L1237F mutation within RAD50, a component of the Mre11 double strand break repair complex, which resulted in heightened sensitivity to the combination of checkpoint inhibition and clastogenic chemotherapy. We validated the WGS findings using a combination of an exon capture assay and validation in model systems. The tumor samples sequenced by exon capture were derived from tissue taken from both the initial and second surgeries.
Link
Palabras clave
Versiones (1)
- 10/1/23 10/1/23 - Chiara Middel
Titular de derechos de autor
Barry S. Taylor, PhD, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA
Subido en
10 de enero de 2023
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
dbGaP phs000706 RAD50 Hypomorphism as Basis for Response to Chemotherapy
Subject ID, consent group, subject source, and subject source ID of subject with ureteral neoplasm and involved in the "Genome Sequencing Reveals That RAD50 Hypomorphism Results in Enhanced Sensitivity to Checkpoint Kinase Inhibition Combined with Chemotherapy" project.
- StudyEvent: SEV1
- Subject ID, consent group, subject source, and subject source ID of subject with ureteral neoplasm and involved in the "Genome Sequencing Reveals That RAD50 Hypomorphism Results in Enhanced Sensitivity to Checkpoint Kinase Inhibition Combined with Chemotherapy" project.
- Subject ID, sample ID, sample source, sample source ID, and sample use variable obtained from subject with ureteral neoplasm and involved in the "Genome Sequencing Reveals That RAD50 Hypomorphism Results in Enhanced Sensitivity to Checkpoint Kinase Inhibition Combined with Chemotherapy" project.
- Subject ID and sex of subject with ureteral neoplasm and involved in the "Genome Sequencing Reveals That RAD50 Hypomorphism Results in Enhanced Sensitivity to Checkpoint Kinase Inhibition Combined with Chemotherapy" project.
- Sample ID, body site where sample was obtained, analyte type, tumor status of sample, histological type of sample, primary tumor or metastasis, primary tumor location, tumor stage, and tumor treatment of subject with ureteral neoplasm and involved in the "Genome Sequencing Reveals That RAD50 Hypomorphism Results in Enhanced Sensitivity to Checkpoint Kinase Inhibition Combined with Chemotherapy" project.
Similar models
Subject ID, consent group, subject source, and subject source ID of subject with ureteral neoplasm and involved in the "Genome Sequencing Reveals That RAD50 Hypomorphism Results in Enhanced Sensitivity to Checkpoint Kinase Inhibition Combined with Chemotherapy" project.
- StudyEvent: SEV1
- Subject ID, consent group, subject source, and subject source ID of subject with ureteral neoplasm and involved in the "Genome Sequencing Reveals That RAD50 Hypomorphism Results in Enhanced Sensitivity to Checkpoint Kinase Inhibition Combined with Chemotherapy" project.
- Subject ID, sample ID, sample source, sample source ID, and sample use variable obtained from subject with ureteral neoplasm and involved in the "Genome Sequencing Reveals That RAD50 Hypomorphism Results in Enhanced Sensitivity to Checkpoint Kinase Inhibition Combined with Chemotherapy" project.
- Subject ID and sex of subject with ureteral neoplasm and involved in the "Genome Sequencing Reveals That RAD50 Hypomorphism Results in Enhanced Sensitivity to Checkpoint Kinase Inhibition Combined with Chemotherapy" project.
- Sample ID, body site where sample was obtained, analyte type, tumor status of sample, histological type of sample, primary tumor or metastasis, primary tumor location, tumor stage, and tumor treatment of subject with ureteral neoplasm and involved in the "Genome Sequencing Reveals That RAD50 Hypomorphism Results in Enhanced Sensitivity to Checkpoint Kinase Inhibition Combined with Chemotherapy" project.
C0441833 (UMLS CUI [1,2])
C0242481 (UMLS CUI [1,2])
C0449416 (UMLS CUI [1,2])
C0681850 (UMLS CUI [1,3])
C3847505 (UMLS CUI [1,2])
C0449416 (UMLS CUI [1,3])